WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Consensus Target Price of $21.53

WAVE Life Sciences Ltd. (NASDAQ:WVE) has been given an average recommendation of “Moderate Buy” by the twenty analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, fifteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $20.89.

A number of equities research analysts have issued reports on WVE shares. HC Wainwright initiated coverage on shares of WAVE Life Sciences in a research note on Wednesday. They set a “strong-buy” rating on the stock. Leerink Partners set a $10.00 target price on WAVE Life Sciences in a report on Tuesday. Mizuho decreased their price target on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Wedbush set a $13.00 price target on WAVE Life Sciences in a research note on Friday, October 2nd. Finally, JPMorgan Chase & Co. began coverage on WAVE Life Sciences in a report on Wednesday, September 23rd. They set a “neutral” rating for the company.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported third-quarter revenue of $13.16 million, well above the $4.51 million analyst consensus, while its $0.30 per-share loss was narrower than the expected $0.33 loss. The results helped ease concerns about the company’s financial performance and contributed to a recent share-price rally. Wave Life Sciences stock rallies as Q3 results ease loss fears
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong-Buy” rating, offering a favorable view of WAVE’s long-term prospects. The firm forecasts a $1.09-per-share loss for fiscal 2026 and fiscal 2027, improving to losses of $0.79 in fiscal 2028, $0.68 in fiscal 2029 and $0.47 in fiscal 2030. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, ranging from $0.26 to $0.31 per share through the near-term reporting periods. The estimates imply that investors will likely focus on clinical progress, revenue growth and the company’s ability to reduce cash burn rather than near-term profitability.
• Negative Sentiment: Despite beating estimates, WAVE remains deeply unprofitable, with a negative net margin and analyst expectations for another full-year loss. Its shares also remain well below the 52-week high, reflecting continuing execution and biotechnology-sector risks.

WAVE Life Sciences Stock Performance

WVE opened at $3.59 on Friday. The firm has a market cap of $708.06 million, a P/E ratio of -3.36 and a beta of -1.43. WAVE Life Sciences has a 52-week low of $3.04 and a 52-week high of $21.73. The business’s fifty day moving average is $4.07 and its 200-day moving average is $7.49.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. WAVE Life Sciences had a negative return on equity of 44.66% and a negative net margin of 296.86%. The company had revenue of $13.16 million for the quarter, compared to analysts’ expectations of $4.51 million. On average, research analysts predict that WAVE Life Sciences will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Heidi L. Wagner sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the transaction, the director directly owned 44,930 shares in the company, valued at approximately $270,029.30. This represents a 13.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 23,564 shares of company stock worth $132,476. 24.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On WAVE Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC increased its holdings in WAVE Life Sciences by 68.0% in the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock valued at $14,766,000 after purchasing an additional 1,029,052 shares during the period. Renaissance Technologies LLC increased its stake in shares of WAVE Life Sciences by 152.6% in the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock valued at $4,330,000 after buying an additional 360,800 shares during the period. Readystate Asset Management LP acquired a new stake in shares of WAVE Life Sciences in the second quarter valued at about $27,465,000. Y Intercept Hong Kong Ltd bought a new position in shares of WAVE Life Sciences during the first quarter worth about $1,138,000. Finally, Capstone Capital Management Ltd bought a new position in shares of WAVE Life Sciences during the first quarter worth about $1,044,000. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.